Javier Oesterheld

Clinical (Full) Professor

Wake Forest University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Introduction: The survival rate of patients with Ewing sarcoma (ES) has seen slow improvement over the past several decades and remains dismal for those with recurrent or metastatic disease. Initial clinical trials in relapsed/refractory ES with single agent targeted therapies, or combinations of single agents, have not yet improved patient outcomes. To overcome this barrier, the Molecular Targeted Therapeutics Laboratory has developed by in silico design “first in class” small molecule multikinase inhibitors (MKIs) which simultaneously target multiple tumor-promoting pathways with a single drug at nM potency. LCI133 (CDK4/6/CDK9) and LCI139 (PI3K/CDK4/6/CDK9) potently inhibit key kinases that control mitogenic signaling, proliferation, and transcription. The purpose of this study is to evaluate the potency, efficacy, and toxicity of LCI133 and LCI139 in ES model systems. Methods: ES cell lines and normal human skeletal muscle cells (SkMC) were treated with MKIs in logarithmic fashion and IC50s were determined by CellTiter-Glo 2.0 viability assays. Incucyte® Annexin V Dye was used to evaluate apoptosis over time by Incucyte® S3 following MKI treatment. Cell cycle analysis was performed over time using Incucyte® Cell Cycle Lentivirus Reagent and analyzed using an Incucyte® S3. Western blot and qPCR analysis was used to assess protein and RNA expression changes, respectively, of targeted pathways to confirm on-target activity of these MKIs following 3-24 hr treatment. Results: LCI133 and LCI139 were nanomolar potent in ES cell lines TC71 (392.5nM/312nM) and A673 (471.5nM/407.4nM), while only LCI139 was nanomolar potent in the RDES (262.2nM) cell line. Critically, LCI133 and LCI139 were less toxic against SkMC compared to single agent CDK9 inhibitors. In TC71 and A673 cells, both compounds induced statistically significant dose-dependent apoptosis, as well as G1 phase cell cycle arrest. Three hr LCI133 and LCI139 treatment decreased expression of CDK9-RNA polymerase II response genes MCL1 (P ≤ 0.001) and MYC (P ≤ 0.001). 24 hr treatment had differential effects on pRb and pAKT levels. pRpb1 and MCL-1 were reduced in all cell lines by LCI139 and/or LCI133. Increased cleaved PARP (cPARP) was observed in all cell lines following 24 hr treatment with LCI133 and LCI139 confirming the induction of apoptosis. Conclusion: Novel small molecule MKIs allow for the simultaneous targeting of multiple pathways while mitigating the toxicity of single agent combination therapy. This is a promising potential treatment strategy for ES patients for whom new treatment approaches are desperately needed. These studies provide preclinical evidence of the potential efficacy of small molecule MKIs in ES and support the future efforts of in vivo models evaluating efficacy and safety of these agents. Citation Format: Kaitlyn H. Smith, Cody C. McHale, Kenzie Wells, Krishnaiah Maddeboina, Kimberly Q. McKinney, Poornima Gourabathini, Jeffrey S. Huo, Donald L. Durden, Javier Oesterheld. Efficacy of novel CDK9/CDK4/6/PI3K triple inhibitors, LCI133 and LCI139, in Ewing sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3006.

Year:

2025

Background: Ewing sarcoma (ES) is an aggressive malignancy and there is an unmet need for more effective treatment options for patients. Histone deacetylases (HDACs) have been shown to be involved in ES tumorigenesis and HDAC inhibitors have been investigated in the context of ES. Our objective for this study was to investigate the efficacy and mechanism of action of HDAC inhibition in vitro and in vivo in ES models, alone and in combination with standard of care therapies. Methods/Results: HDAC inhibitors were tested for in vitro efficacy against ES cell lines and romidepsin was found to be most effective. The mechanistic changes induced by romidepsin were investigated by Western blotting and proteins involved in cell cycle progression and DNA damage repair were found to be repressed. In vitro we identified that romidepsin synergizes with doxorubicin and etoposide and that it increases the efficacy of the standard of care combinations VDC/IE. Further, the combination treatments lead to an increase in caspase 3/7 cleavage, a decrease in DNA damage repair proteins, and an accumulation of DNA damage. In vivo, the combination of romidepsin and ifosfamide/etoposide (IE) leads to a significant decrease in tumor volume compared to that of IE alone. Conclusions: Our data indicates that romidepsin improves efficacy of chemotherapeutic agents in vitro and leads to a decreased tumor volume in vivo, suggesting that the addition of romidepsin may improve upfront treatment in ES patients.

Year:

2025

Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal antibody naxitamab and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with cyclophosphamide and topotecan between August 2021 and December 2022. This combined chemoimmunotherapy regimen was well tolerated in these heavily pretreated patients with R/R HR neuroblastoma who had few treatment options and overall poor prognoses.

Year:

2025

Year:

2025

PURPOSE Long-term survival in high-risk neuroblastoma (HRNB) is approximately 50%, with mortality primarily driven by relapse. Eflornithine (DFMO) to reduce risk of relapse after completion of immunotherapy was investigated previously in a single-arm, phase II study (NMTRC003B; ClinicalTrials.gov identifier: NCT02395666 ) that suggested improved event-free survival (EFS) and overall survival (OS) compared with historical rates in a phase III trial (Children Oncology Group ANBL0032; ClinicalTrials.gov identifier: NCT00026312 ). Using patient-level data from ANBL0032 as an external control, we present new analyses to further evaluate DFMO as HRNB postimmunotherapy maintenance. PATIENTS AND METHODS NMTRC003B (2012-2016) enrolled patients with HRNB (N = 141) after standard up-front or refractory/relapse treatment who received up to 2 years of continuous treatment with oral DFMO (750 ± 250 mg/m 2 twice a day). ANBL0032 (2001-2015) enrolled patients with HRNB postconsolidation, 1,328 of whom were assigned to dinutuximab (ch.14.18) treatment. Selection rules identified 92 NMTRC003B patients who participated in (n = 87) or received up-front treatment consistent with (n = 5) ANBL0032 (the DFMO/treated group) and 852 patients from ANBL0032 who could have been eligible for NMTRC003B after immunotherapy, but did not enroll (the NO-DFMO/control group). The median follow-up time for DFMO/treated patients was 6.1 years (IQR, 5.2-7.2) versus 5.0 years (IQR, 3.5-7.0) for NO-DFMO/control patients. Kaplan-Meier and Cox regression compared EFS and OS for overall groups, 3:1 (NO-DFMO:DFMO) propensity score–matched cohorts balanced on 11 baseline demographic and disease characteristics with exact matching on MYCN, and additional sensitivity analyses. RESULTS DFMO after completion of immunotherapy was associated with improved EFS (hazard ratio [HR], 0.50 [95% CI, 0.29 to 0.84]; P = .008) and OS (HR, 0.38 [95% CI, 0.19 to 0.76]; P = .007). The results were confirmed with propensity score–matched cohorts and sensitivity analyses. CONCLUSION The externally controlled analyses presented show a relapse risk reduction in patients with HRNB treated with postimmunotherapy DFMO.

Year:

2024

Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (14)

Eric Sandler

Department Chair

Nemours Children's Health System

UNITED STATES
View details

Christine A Pratilas

Vice Chair for Pediatric Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

David Loeb

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Masanori Hayashi

Assistant Professor

University of Colorado Boulder

UNITED STATES
View details

Leo Mascarenhas

Division Chief and Director, Pediatric Hematology-Oncology, Guerin Children's; Director, Sarcoma Program, Cedars-Sinai Cancer

Cedars-Sinai Medical Center

UNITED STATES
View details

Giselle L. Saulnier Sholler

-

UNITED STATES
View details

Jun Yin

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jeffrey Huo

Clinical Assistant Professor

Wake Forest School of Medicine

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Emi Caywood

Director, Transplant and Cellular Therapy

Alfred I DuPont Hospital for Children

UNITED STATES
View details

Matteo Trucco

Associate Professor

Cleveland Clinic

UNITED STATES
View details

Anthony Audino

Professor of Pediatrics

Nationwide Children's Hospital

UNITED STATES
View details

Scott Borinstein

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Lars Wagner

division of pediatric hematology‐oncology duke university medical center durham north carolina usa

UNITED STATES
View details